Antigenics Oncophage On Hold After Phase III Failure, Conflicting Preliminary Data
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Antigenics is shifting its focus to its Phase I and preclinical development programs following the failure of its therapeutic vaccine Oncophage in a Phase III renal cell carcinoma (RCC) trial, the company said